Boehringer Ingelheim partners CDR-Life to develop antibody based therapeutics for Geographic Atrophy
Together the partners will advance CDR-Life’s preclinical antibody fragments targeting a key pathway in geographic atrophy (GA) besides developing novel treatments and technologies for patients who have only inadequate treatment options